Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for KalVista Pharmaceuticals (KALV) over the last 10 years, with Q2 2025 value amounting to $10.5 million.

  • KalVista Pharmaceuticals' Other Working Capital Changes rose 62583.1% to $10.5 million in Q2 2025 from the same period last year, while for Apr 2025 it was $10.6 million, marking a year-over-year increase of 187100.37%. This contributed to the annual value of $10.6 million for FY2025, which is 186245.35% up from last year.
  • As of Q2 2025, KalVista Pharmaceuticals' Other Working Capital Changes stood at $10.5 million, which was up 62583.1% from -$2.1 million recorded in Q4 2024.
  • In the past 5 years, KalVista Pharmaceuticals' Other Working Capital Changes ranged from a high of $10.5 million in Q2 2025 and a low of -$2.1 million during Q4 2024
  • Over the past 3 years, KalVista Pharmaceuticals' median Other Working Capital Changes value was $783000.0 (recorded in 2024), while the average stood at $1.4 million.
  • In the last 5 years, KalVista Pharmaceuticals' Other Working Capital Changes crashed by 2193.42% in 2024 and then soared by 62583.1% in 2025.
  • KalVista Pharmaceuticals' Other Working Capital Changes (Quarter) stood at -$1.8 million in 2023, then decreased by 19.27% to -$2.1 million in 2024, then soared by 598.15% to $10.5 million in 2025.
  • Its last three reported values are $10.5 million in Q2 2025, -$2.1 million for Q4 2024, and $783000.0 during Q3 2024.